
Genentech’s Tecentriq Receives FDA Priority Review in Stage III Colon Cancer
Genentech’s Tecentriq Moves Closer to Potential New Standard of Care in Early Colon Cancer Following FDA Priority Review Acceptance Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental…











